Securities Code: 300142 Securities Abbreviation: Wason Bio-technology Announcement No.: 2026-061
Yunnan Wason Bio-technology Co., Ltd.
Announcement of Resolutions of the Seventh Meeting of the Sixth Board of Directors
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from any false representations, misleading statements, or material omissions.
I. Convening of the Board Meeting
The Seventh Meeting of the Sixth Board of Directors of Yunnan Wason Bio-technology Co., Ltd. (hereinafter referred to as the "Company") was held on August 3, 2026, in the Company's conference room, combining on-site and teleconference methods. The meeting notice was sent via email on July 29. A total of 11 directors were eligible to attend, and 11 directors actually attended. The meeting was chaired by Chairman Li Yunchun, and the Company's Secretary of the Board and some senior management personnel were present. The convening and holding of this meeting comply with the requirements of the "Company Law of the People's Republic of China" (hereinafter referred to as the "Company Law"), laws, regulations, and the Articles of Association.
II. Deliberation of the Board Meeting
- Deliberation and Approval of the "Proposal on Increasing the Total Amount of Raised Funds for the Company's 2026 Private Placement of A Shares and Adjusting the Issuance Plan"
In accordance with the relevant provisions of laws, regulations, and normative documents such as the "Company Law," the "Securities Law of the People's Republic of China" (hereinafter referred to as the "Securities Law"), the "Administrative Measures for the Registration of Equity Issuance by Listed Companies," and the "Guiding Opinions on the Application of Securities and Futures Laws No. 18," and in conjunction with the Company's actual situation, the total amount of raised funds, pricing benchmark date, issuance price, and issuance volume for the Company's 2026 private placement of A shares (hereinafter referred to as the "Current Issuance" or "Current Private Placement") have been adjusted.
The Company's Board of Directors deliberated and approved the Current Issuance plan item by item, with the specific contents as follows:
(1) Total Amount of Raised Funds
Before adjustment:
The total amount of funds expected to be raised from the Current Issuance shall not exceed RMB 200,288.35 million, and the raised funds, after deducting issuance expenses, will be used to supplement working capital.
After adjustment:
The total amount of funds expected to be raised from the Current Issuance shall not exceed RMB 220,317.19 million, and the raised funds, after deducting issuance expenses, will be used to supplement working capital.
Mr. Li Yunchun, as a related director, abstained from voting on this proposal. The proposal was voted on by other non-related directors.
Voting results: 10 votes in favor, 0 votes against, 0 abstentions.
(2) Pricing Benchmark Date and Issuance Price
The pricing benchmark date for the Current Issuance is the announcement date of the resolution of the Third Meeting of the Sixth Board of Directors. The issuance price for the Current Issuance is RMB 9.63 per share, which is not less than 80% of the average daily trading price of the Company's shares in the 20 trading days prior to the pricing benchmark date (Average daily trading price in the 20 trading days prior to the pricing benchmark date = Total trading volume in the 20 trading days prior to the pricing benchmark date / Total trading volume in the 20 trading days prior to the pricing benchmark date).
The pricing benchmark date for the Current Issuance is the first day of the issuance period. After the China Securities Regulatory Commission (CSRC) approves the registration of the Current Issuance, the issuance period will be determined by the shareholders' meeting authorizing the Board of Directors or its authorized personnel, based on market conditions and the principle of protecting the interests of small and medium investors of the listed company, after careful research and judgment.